Design, Synthesis and Antitumor Activity of Novel Indolin-2-one Derivatives Containing 4-Thiazolidinone Moiety

doi:10.1007/s40242-015-4335-8

Chemical Research in Chinese Universities ›› 2015, Vol. 31 ›› Issue (2): 235-243.doi: 10.1007/s40242-015-4335-8

• Articles • Previous Articles Next Articles

Design, Synthesis and Antitumor Activity of Novel Indolin-2-one Derivatives Containing 4-Thiazolidinone Moiety

LIU Zijian¹, HOU Yunlei¹, ZHANG Guogang², XU Ning¹, MI Bin¹, GONG Ping¹, ZHAO Yanfang¹

1. Key Laboratory of Structure-based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China;
2. State Key Laboratory Breeding Base-Hebei Province Key Laboratory of Molecular Chemistry for Drug, College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, P. R. China

Received:2014-09-05 Revised:2015-01-04 Online:2015-04-01 Published:2015-01-19
Contact: ZHAO Yanfang E-mail:yanfangzhao@126.com
Supported by:
Supported by the Program for Innovative Research Team of the Ministry of Education of China and the Program for Liaoning Innovative Research Team in University, China(No.IRT1073), and the National Natural Science Foundation of China (No.81202405)

Abstract

Abstract:

A series of novel indolin-2-one derivatives containing 4-thiazolidinone moiety(7a―7r) were synthesized and evaluated for their in vitro antitumour activities against MDA-MB-231(human breast cancer), H460(human lung cancer) and HT-29(human colon cancer) cell lines by standard 3-(4,5-dimethylthiazae-2-yl)-2,5-diphenyltetrazo- lium bromide(MTT) assay. Representative compounds(7d, 7k, 7m, 7p) with higher cytotoxicity were further examined against one normal cell line(WI-38, human fetal lung fibroblasts). The preliminary investigation shows that most of the compounds display moderate to excellent potency and high selectivity against different human cancer cell lines. In particular, the most potent compound 7m shows promising cytotoxicity against MDA-MB-231, H460 and HT-29 cell lines with IC₅₀ values of 0.78, 0.056 and 0.018 μmol/L, respectively. The potency is much higher than that of Sunitinib(IC₅₀=3.46 μmol/L against MDA-MB-231, IC₅₀=2.59 μmol/L against H460, IC₅₀=1.50 μmol/L against HT-29) by 4.4, 46.3 and 83.3 fold.

Key words: Indolin-2-one, 4-Thiazolidinone, Antitumour activity

LIU Zijian, HOU Yunlei, ZHANG Guogang, XU Ning, MI Bin, GONG Ping, ZHAO Yanfang. Design, Synthesis and Antitumor Activity of Novel Indolin-2-one Derivatives Containing 4-Thiazolidinone Moiety[J]. Chemical Research in Chinese Universities, 2015, 31(2): 235-243.

References

[1] Liao H. M., Chong L. E., Tan L., Chen X. D., You R., Gong P., Chem. Res. Chinese Universities, 2014, 30(5), 759
[2] Krug M., Hilgeroth A., Mini-Rev. Med. Chem., 2008, 8, 1312
[3] Jin K., Zhang X. P., Ma C. H., Xu Y. Y., Yuan Y. M., Xu W. F., Bioorg. Med. Chem., 2013, 21, 2663
[4] Ebos J. M. L., Lee C. R., Cruz-Munoz W., Bjamason G. A., Christensen J. G., Kerbel R. S., Cancer Cell, 2009, 15, 232
[5] Pandit B., Sun Y., Chen P., Sackett D. L., Hu Z., Rich W., Li C., Lewis A., Schaefer K., Li P. K., Bioorg. Med. Chem., 2006, 14, 6492
[6] Roth G. J., Heckel A., Colbatzky F., Handschuh S., Kley J., Lehmann-Lintz T., Lotz R., Tontsch-Grunt U., Walter R., Hilberg F., J. Med. Chem., 2009, 52, 4466
[7] Elbarbary A. A., Khodair A. I., Pedersen E. B., Nielsen C., Monatsh. Chem., 1994, 125, 593
[8] Ottana R., Maccari R., Barreca M. L., Bruno G., Rotondo A., Rossi A., Chiricosta G., di Paola R., Sautebin L., Cuzzocrea S., Vigorita M. G., Bioorg. Med. Chem., 2005, 13, 4243
[9] Vicini P., Geronikaki A., Anastasia K., Incerti M., Zani F., Bioorg. Med. Chem., 2006, 14, 3859
[10] Ottana R., Carotti S., Maccari R., Landini I., Chiricosta G., Caciagli B., Vigorita M. G., Mini E., Bioorg. Med. Chem. Lett., 2005, 15, 3930
[11] Zheng W., Degterev A., Hsu E., Yuan J., Yuan C., Bioorg. Med. Chem. Lett., 2008, 18, 4932
[12] Sharath K., Kothanahally S., Hanumappa A., Hegde M., Narasimhamurthy K. H., Raghavan S. C., Rangappa K. S., Eur. J. Med. Chem., 2014, 81, 341
[13] Cutshall N. S., O'Day C., Prezhdo M., Bioorg. Med. Chem. Lett., 2005, 15, 3374
[14] Ahn J. H., Kim S. J., Park W. S., Cho S. Y., Ha J. D., Kim S. S., Kang S. K., Jeong D. G., Jung S. K., Lee S. H., Kim H. M., Park S. K., Lee K. H., Lee C. W., Ryu S. E., Choi J. K., Bioorg. Med. Chem. Lett., 2006, 16, 2996
[15] Degterev A., Lugovskoy A., Cardone M., Mulley B., Wagner G., Mitchison T., Yuan J., Nat. Cell Biol., 2001, 3, 173
[16] Zimenkovsky B., Kazmirchuk G., Zaprutko L., Paraskiewicz A., Melzer E., Lesyk R., Ann. Polish Chem. Soc., 2005, 1, 69
[17] Wang S. B., Zhao Y. F., Zhang G. G., Lü Y. X., Zhang N., Gong P., Eur. J. Med. Chem., 2011, 46, 3509
[18] Vartale S. P., Pawar Y. D., Halikar N. K., Heterocyclic Letters, 2012, 2, 311
[19] Havrylyuk D., Mosula L., Zimenkovsky B., Vasylenkoc O., Gzellab A., Lesyk R., Eur. J. Med. Chem., 2010, 45, 5012
[20] Beauchard A., Laborie H., Rouillard H., Lozach O., Ferandin Y., Guével R. L., Guguen-Guillouzo C., Meijer L., Besson T., Thiéry V., Bioorg. Med. Chem., 2009, 17, 6257
[21] Mologni L., Rostagno R., Brussolo S., Knowles P. P., Kjaer S., Murray-Rust J., Rosso E., Zambon A., Scapozza L., McDonald N. Q., Lucchini V., Gambacorti-Passerini C., Bioorg. Med. Chem., 2010, 18, 1482
[22] Ohishi Y., Mukai T., Nagahara M., Yajima M., Kajikawa N., Miyahara K., Takano T., Chem. Pharm. Bull., 1990, 38, 1911
[23] Momose Y., Meguro K., Ikeda H., Hatanaka C., Oi S., Sohda T., Chem. Pharm. Bull., 1991, 39, 1440

Design, Synthesis and Antitumor Activity of Novel Indolin-2-one Derivatives Containing 4-Thiazolidinone Moiety

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments